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 ABSTRACT 
Nicotinic acetylcholine receptors are ligand-gated ion channels. These receptors 
play important roles in physiological as well as pathophysiological processes. The present 
work was aimed at studying three questions that were centered on pharmacology, 
expression and physiology of nicotinic receptors.  
The first chapter describes the results of work that was aimed at understanding the 
molecular determinants of interaction between α-conotoxin BuIA and complementary 
subunits of nicotinic acetylcholine receptors.  Proline 6 of BuIA was found to be a major 
determinant of binding to nAChR β2 subunit. Coupling between proline 6 and the residue 
at 59
th
 position of the β subunit was found to be equal to 2.4 kcal/mol. This work paves 
the ground for creating selective ligands that discriminate between α3β2 and α3β4 
receptors. 
 The second chapter describes the dependence of expression of human α9-
containing nicotinic acetylcholine receptors in the Xenopus laevis oocyte expression 
system on the 5’leader sequence of the α9 subunit. The human α9 subunit was 
determined to be the limiting factor in the functional expression of α9-containing 
receptors. The inclusion of the 5’leader from alfalfa mosaic virus before the α9 coding 
sequence facilitated the expression of human α9 homomeric receptors by ~70 fold and 




expression levels of α9-containing nAChRs; this advance allows reliable testing of new 
compounds that target human α9-containing receptors. 
The third chapter describes results of work aimed at understanding the interaction 
between rat nicotinic α9α10 and purinergic receptors. Comparison of currents from 
coactivation of receptors to the predicted currents gave inconclusive results. Comparison 
of agonist sensitivities for purinergic receptors when receptors are expressed alone and 
when they are coinjected revealed ~1.6-fold difference in sensitivity, with P2X4 receptors 
less sensitive to ATP when α9α10 receptors are coexpressed. Interactions between rat 

















ABSTRACT ........................................................................................................... iii 
LIST OF TABLES ................................................................................................. vi 
LIST OF FIGURES .............................................................................................. vii 
Chapters 
1 INTERACTION BETWEEN α-CONOTOXIN BuIA AND THE β-  
SUBUNIT OF NICOTINIC ACETYLCHOLINE RECEPTORS ...............1 
Introduction ..................................................................................................2 




2 5’ UNTRANSLATED REGION OF HUMAN α9 SUBUNIT IS  








3 INTERACTION BETWEEN NICOTINIC ACETYLCHOLINE 
RECEPTORS AND PURINERGIC RECEPTORS...................................50 
 
Introduction ................................................................................................51 








LIST OF TABLES 
1.1 BuIA analogs ...............................................................................................................14 
 
1.2 Selected α-conotoxin sequences demonstrate a highly conserved proline 
      residue in the first intercysteine loop ...........................................................................15 
 
1.3 IC50s and calculated coupling energies ........................................................................17 
 
2.1 Comparison of the functional expression of receptors following co-injection  
      of cRNA for subunits of different species ...................................................................43 
 
2.2 Comparison of the functional expression of receptors upon co-injection of  
      different ratios of cRNA for specific subunit ..............................................................43 
 
2.3 Insertion of AMV improves the expression of human α9 homomeric 
      receptors .......................................................................................................................43 
 
2.4 AMV improves the expression of human α9α10 heteromeric receptors .....................44 
 
3.1 Results suggesting inhibition .......................................................................................61 
 
3.2 Results suggesting independent function .....................................................................61 
 
3.3 EC50 values for ATP on rat P2X4 receptors under different experimental  
conditions .....................................................................................................................62 
 
3.4 EC50 values for ACh on rat α9α10 receptors under different experimental 
conditions .....................................................................................................................62 
 
3.5 Analysis of possible interaction between rat α9α10 and rat P2X7 receptors in  
barium-containing ND96 .............................................................................................62   
 
3.6 EC50 for ACh on rat α9α10 alone and coinjected with rat P2X7 in Ba-ND96 .............63 
 






LIST OF FIGURES 
Figure 
 
1.1 Mutations in α-conotoxin BuIA differentially affect α3β2 vs. α3β4 nAChRs ............19 
 
1.2 Sequence alignment of rat and human β2 and β4 nAChR subunits .............................20 
 
1.3 Coupling coefficient values for toxin-receptor mutant pairs .......................................20 
 
1.4 Concentration-response curves for BuIA[P6O] on rα3β2 and rα3β4 nAChRs ...........21 
 
1.5 Concentration-response of toxin analogs tested on receptor mutants ..........................22 
 
1.6 Position 59 of the β subunit alters kinetics of toxin unblock .......................................24 
 
2.1 Comparison between the levels of exogenous expression of rat and human α9- 
      containing nAChRs in X.laevis oocytes .......................................................................45 
 
2.2 Comparison between the level of expression of human α9/rat α10 (hα9rα10) and rat 
      α9/human α10 (rα9hα10) receptors .............................................................................46 
 
2.3 Comparison of functional receptor expression following injection of different ratios 
      of receptor subunit cRNA ............................................................................................47 
 
2.4 Comparison of the 5’ untranslated regions in human α9, human α10, rat α9, and rat 
      α10 subunits .................................................................................................................48 
 
2.5 AMV improves the level of functional expression of α9-containing nAChRs ............49 
 
3.1 Representative traces (A) and bar graph (B) summarizing the results suggesting 
      interaction between rat α9α10 and P2X4 receptors ......................................................64 
 
3.2 Representative traces (A) and bar graph (B) summarizing the results suggesting 
      independent function of rat α9α10 and P2X4 receptors heterologously expressed in 
      oocytes of Xenopus laevis frog ....................................................................................65 
 




3.4 Comparison between ACh EC50 in calcium vs. barium-containing ND96 ..................67 
 
3.5 Graphical representation of results for rat α9α10 – P2X7 interaction ..........................68 
 












































INTERACTION BETWEEN α-CONOTOXIN BuIA AND THE β-SUBUNIT OF 
 






































 Neuronal nicotinic acetylcholine receptors (nAChRs) together with GABAA, 
GABAc, glycine, and 5-HT3 receptors belong to the group of ligand-gated ion channels. 
In the mammalian genome eleven neuronal nAChR subunits genes have been identified 
(α2-α7, α9-α10, and β2-β4). Functional neuronal nAChRs are homo- or heteropentamers. 
α7 and α9 subunits are able to assemble as homopentamers, α2-α6 subunits require β2-β4 
subunits to make heteropentamers, α10 forms a heteromer with α9 (1,2). Neuronal 
nicotinic acetylcholine receptors are found in various neuronal and non-neuronal tissues 
and organs. In the central and peripheral nervous systems, neuronal nAChRs are found at 
presynaptic and postsynaptic sites and they contribute both to neurotransmission and 
modulation of release of several neurotransmitters including dopamine, glutamate and 
GABA (3). Non-neuronal localizations of neuronal nAChRs include keratinocytes, 
cochlear hair cells, lymphoid tissue, macrophages, epithelial cells in airways, vascular 
tissue, astrocytes and placenta (4,5). 
  Due to such broad representation throughout the organism, nAChRs have been 
implicated in a range of physiological and pathophysiological functions related to 
cognition, reward, arousal, learning and memory, motor control, antinociception, immune 
function and nicotine addiction (6,7). Unfortunately, the rational design of selective 
ligands to target a particular receptor subtype is challenging due to several factors. First, 
there is considerable conservation of nAChR residues (among different subunits) that 
form the ligand-binding sites. Second, the three-dimensional structure of the ligand 
binding site of nAChRs is not fully resolved. Current knowledge about the structure of 




the muscle nAChR from an electric organ of Torpedo californica (8) and the crystal 
structure of the ACh-binding protein (AChBP), a soluble protein expressed by glial cells 
of  fresh water snails. Although detailed models of neuronal nAChRs have been 
constructed based on these structures, these models may not fully account for known 
ligand activity (9).  Third, many ligands show poor selectivity toward a particular 
receptor subtype. For example, antagonists mecamylamine and dihidro-β-erythroidine do 
not discriminate well among different heteromeric neuronal nAChRs.    
  Small disulfide rich peptides known as conotoxins found in the venom of 
predatory Conus snails have facilitated the search for and rational design of selective 
ligands. Conotoxins have among their targets different voltage and ligand gated ion 
channels, GPCRs, and norepinephrine transporters (10). α-Conotoxins target nAChRs 
(11,12), and compete with ACh at its binding site, which is formed at the interface 
between neighboring subunits. Some α-conotoxins show preference toward a particular 
nAChR subtype. For example, α-conotoxin ImI selectively blocks α7 and α3β2 nAChRs 
(13,14), α-conotoxin MII shows high selectivity for α6β2 and α3β2 nAChRs (15,16), and 
α-conotoxin RgIA targets α9α10 nAChRs  (17).  
  α-conotoxin BuIA is a structurally unique 13 amino acid peptide with α-4/4 Cys 
spacing (number of residues between cysteine residues). Interestingly, α-conotoxin BuIA 
can kinetically discriminate between nAChRs that contain a β2 vs. β4 subunit; the off-
rate for all β4- containing nAChRs is slow compared to all corresponding β2-containing 
nAChR subtypes (18). We previously identified residue differences between  and 
 nAChRs that interact with BuIA. In the present study we examined residues in 




double-mutant cycle analysis to investigate pair-wise interaction between toxin and 
receptor. Our results indicate that Pro6 of α-conotoxin BuIA interacts with residue 59 of 
the β subunit.  Our results further indicate that this interaction may be exploited in order 
to create selective ligands for β4-containing nAChRs.  
Materials and methods 
Chemical synthesis 
 -Conotoxin BuIA and toxin’s analogs were synthesized on an amide resin using 
Fmoc chemistry and standard side protection, except on cysteine residues. Cys residues 
were protected in pairs with either S-trityl on Cys2 and Cys8, or S-acetamidomethyl on 
Cys3 and Cys13. The peptide was removed from the resin and precipitated. A two-step 
oxidation protocol was used to selectively fold the peptides as described previously (19). 
Receptors mutagenesis 
Point mutations were introduced into 2 and 4 subunits using a QuickChange 
site-directed mutagenesis kit (Stratagene). The receptors were in pGEMHE, pSP64, 
pSP65 or pBlueScript SK(-) vectors. The clones for rat α3 in pSP64 vector, β2 in pSP65 
vector and rat β4 in pBS SK(-) vector  were provided by S. Heinemann (Salk Institute, 
San Diego, CA, USA). The clones for rat β2 and rat β4 receptors in the pGEMHE vector 
were provided by Chuck Luetje (University of Miami, Miami, FL, USA). 
 All mutations were confirmed by sequencing. The notation for point mutants is to 
list the naturally occurring residue, its position, and residue to which it is changed. For 






 Capped cRNA for injection into oocytes was prepared from linearized plasmid 
cDNA using the mMessage mMachine kit (Ambion, Austin, TX). cRNA was purified using 
Qiagen RNeasy kit (Qiagen, Valencia, CA). Oocytes were prepared as described previously 
(15). Fifty nl of cRNA (150 ng/l of each subunit) was injected into individual Xenopus 
oocytes. Injected oocytes were kept at 17°C in ND96 supplemented with antibiotics. All 
recordings were made 1-7 days after injection. 
An injected oocyte was placed in a 30 l recording chamber fabricated from 
Sylgard, and gravity-perfused with ND96 (96.0 mM NaCl, 2.0 mM KCl, 1.8 mM CaCl2, 
1.0 mM MgCl2, 5 mM HEPES, pH 7.1-7.5) containing 1M atropine (ND96A) at a rate 
of 2 ml/min as previously described (15). All solutions also contained 0.1 mg/mL of 
bovine serum albumin to reduce nonspecific adsorption of toxin. ACh-evoked currents 
were recorded with a two-electrode voltage-clamp amplifier (model OC-725 B, Warner 
Instrument Corp., Hamden, CT). The membrane potential was clamped at -70 mV, the 
current signal was low pass-filtered (5 Hz cut-off) and digitized at a sampling frequency 
of 20 Hz.  
The ACh pulse to the oocyte was applied for 1 s. This was automatically done 
every minute. The concentration of ACh was 100 M for all experiments. ACh was 
diluted in ND96A. For the control responses the ACh pulse was preceded by perfusion 
with ND96A. For test responses, the oocyte was exposed to toxin, either by 5- minute 
static bath application or by continuous perfusion with toxin solution until equilibrium. 
The average of three control responses just preceding a test response was used to 




curve represents the average ± SE of measured response of at least three oocytes. Dose-
response curves were fit with Prism software (Graph Pad Software Inc, San Diego, CA) 
to the equation: % response = 100/(1+([toxin]/IC50)^nH), where nH is the Hill 
coefficient.  
Double mutant cycle analysis 
                                           G(X,Y)=G(X) + G(Y) + Gint                    (Eq. 1.1),                                                                   
where G(X) represents the free energy change caused by a mutation of residue X in the 
toxin relative to its wild type, G(Y) represents the change in free energy caused by 
mutation  of residue Y in the receptor relative to its wild type. G(X, Y) represents free 
energy change from both mutations; Gint is a coupling energy, the measure of the 
interactions of the two mutated components. If the two residues do not interact with each 
other, then Gint will equal 0. If the residues interact then Gint will substantially 
differ from 0. 
Gint is described in terms of equilibrium constants: 
                                      Gint = -RTln()                                                           (Eq. 1.2), 
where R-gas constant, 1.986cal/K∙mol; T-absolute temperature, in our case T=293K, Ω- 
Omega, calculated as 
                 Ω=(Kd(WtWr)×Kd(MtMr))/(Kd(WtMr)×(Kd(MtWr))                          (Eq.1. 3) 







Design of toxin analogs 
α-Conotoxins are small peptides, structurally characterized by two conserved 
disulfide bonds that link the first and third and the second and fourth Cys residues, 
forming two loops. The size of the loops in different -conotoxins is variable; in addition 
the residues within each loop are hypervariable and account for subtype selectivity (11).   
 To identify candidate toxin residues that contribute to binding selectivity of α-
conotoxin BuIA, we mutated all residues positioned within the two Cys-loops of the 
peptide (Table 1.1).  
Ala was substituted for all residues other than Pro (or Ala).  Pro6 and Pro7 
constrain the structure of the peptide (20), and Ala substitution at these positions might 
substantially alter the structure of the peptide. We therefore mutated Pro residues to 4(R)-
hydroxyproline and/or 3-(R)-hydroxyproline. 4(R)-Hydroxyproline is a naturally 
occurring variant of Pro found in Conus peptides (21).    
Activity of toxin analogs on  and nAChRs 
-Conotoxin BuIA analogs were tested for activity against and  
nAChRs heterologously expressed in Xenopus oocytes.  Results are shown in Fig. 1.1.  
The results indicate that substitution of hydroxyproline for Pro6 substantially 
reduced activity at  nAChRs. At 10 μM concentration BuIA[P6O] inhibited only 
~11% of baseline current (n=5), whereas native peptide abolished the current at the same 
concentration.   
Mutation of Thr5, Pro7, Val10, Leu11 and Tyr12 had more modest effects.  




concentration.  In contrast, BuIA[P6O]  at the same concentration abolished activity at 
  nAChRs.  Thus, the results indicated that Pro6 plays a dominant role in toxin 
interaction with the receptor.  Pro in the first Cys loop is a highly conserved feature 
across almost all -conotoxins consistent with a critical functional role (Table 1.2).  We 
therefore focused attention on Pro6 as a candidate for the differences in binding kinetics 
for 2 vs. 4 nAChRs (18).   
Interaction of toxin analogs with mutant nAChRs 
To assess the interaction of Pro6 with  subunits of the nAChR, we conducted 
double-mutant cycle analysis (22). Due to a high degree of homology between 2 and 4 
nAChR subunits (Fig. 1.2), the difference in BuIA binding kinetics are likely due to non-
conserved residues between subunits.  Previous work identified three residues on the  
subunit as likely determinants of these BuIA binding properties (23). In the  subunit 
these residues are Thr59, Val111 and Phe119. We therefore initially mutated these three 
nonconserved residues in the 2 subunit to residues that occur in the homologous 
position of the 4 subunit (Lys59, Ile111, and Gln119) (Fig. 1.2).                                                                                                                                                                                         
Double-mutant cycle analysis may be used to identify noncovalent interactions 
between residues of different proteins. Determination of interaction is based on 
alterations in additivity of the free energy resulting from mutation in toxin or receptor 
compared to changes in both toxin and receptor.  If a toxin and a receptor residue are 
interacting, then the sum of the free energy change from the single mutation will not 
equal the sum of the free energy change measured with mutation in toxin and receptor 




Mutant cycle analyses were applied to the toxin analogs to delineate potential 
pair-wise interactions with the  subunit. First, we explored the interaction between Pro6 
(highly conserved among -conotoxins) and Thr59 of the 2 subunit. Substitution of 4-
hydroxyproline for Pro6 decreased the potency of the toxin for wild-type 32 nAChRs 
by almost 3000-fold.  This suggested that hydrophobic interaction with Pro6 is critical for 
binding of the toxin to this particular receptor subtype. Such interaction was disrupted by 
the addition of the hydrophilic 4-hydroxyl group.  In contrast, however, BuIA [P6O] had 
enhanced affinity for an  mutant in which Thr59 was replaced with Lys found in 
the homologous position of the 4 subunit. The results are shown in Fig. 1.3 and Table 
1.3.  The experiment revealed a coupling energy of 2.4 kcal/mol for the BuIA [P6O]-
2T59K pair, indicative of interaction.   
These results prompted us to examine additional mutations in Pro6 and also to 
examine effects of hydroxylation of the adjacent Pro7. 3- Hydroxyproline differs from 4-
hydroxyproline in that the hydroxyl group in the former is adjacent to the -carbon.  
Substitution of Pro6 with the 3-hydroxyproline resulted in a coupling energy of 1.01 
kcal/mol for interaction with residue 59, less than that observed with 4-hydroxyproline.  
We next tested an electron rich 4-(R)-fluoroproline mutation to determine whether the 
electronegative substituent on the 4
th
 - position in Pro influenced the nAChRs binding. 
The BuIA [P6-fluoro] toxin analog was 23 fold less potent on the r32 nAChR. The 
coupling energy for BuIA[P6-fluoro]-2T59K pair was 1.1 kcal/mol, similar in 
magnitude to that observed with the 3-hydroxyproline analog.  
We next wished to assess interaction with the 59
th
 residue of the  subunit as 




Lys59 was substituted with the Thr found in the homologous position of the 2 nAChR 
subunit.  The coupling energy for the BuIA [P6O]-4K59T pair was 2.4 kcal/mol, the 
same as that observed for the BuIA[P6O]-2T59K pair. Thus, BuIA Pro6 couples to the 
59
th
 residue of the  subunit in the environment of the 2 as well as the 4 nAChR 
subunit. We further probed interactions using the 3-hydroxyproline and 4-fluoroproline 
analogs of BuIA. The coupling energies for BuIA[P6O(3)]-β4K59T pair were 1.3 
kcal/mol and  for BuIA[P6-fluoro]-4K59T 0.8 kcal/mol. Both of these values were 
significantly lower than that observed with the P6O analog, consistent with results 
observed for the 2 subunit and residue 59.   
We then probed possible interactions of Pro6 with other residues at the conotoxin 
binding site: Val111 and Phe119 on 2 subunit. Coupling energies for the BuIA[P6O]-
2V111I pair as well as BuIA[P6O(3)]-2V111I pair were 0.1 kcal/mol which indicated 
that there was no interaction between Pro6  and Val 111. The BuIA[P6O]-2F119Q pair 
gave coupling energy of 0.77 kcal/mol, indicative of weak or no interaction. 
BuIA[P6O(3)]-2F119Q and BuIA[P6-fluoro]-2F119Q gave 0.2 kcal/mol and 0.4 
kcal/mol interaction, respectively. We also examined interaction of the neighboring Pro7 
with the  subunit residues.  The results indicated weak or no interaction. The magnitude 
of interaction between each of the two mutation pairs is shown in Fig. 1.3.  
The BuIA Pro6 analog has reversed nAChR subtype selectivity 
 Pro6 of BuIA couples to the 59
th
 residue of the  subunit.   The 59th residue of the 
 subunit differs between 2 and 4 subunits (Fig. 1.2).  This difference potentially 




is five-fold more potent for 32 vs. 34 nAChRs.  In contrast, BuIA[P6O] is 160-fold 
more potent for 34 vs. 32 nAChRs (Fig. 1.4).  Thus, there is a relative shift in 
potency of 800-fold.   
Thr/Lys difference in nAChR subunits causes increased 
potency and slow reversibility of BuIA analogs 
 Each of the Pro6 analogs was tested on wild type 32 and 32T59K where the 
Thr59 present in wild type 2 subunit is replaced with Lys found in the homologous 
position of the 4 subunit. In each instance, the Pro6 analog was substantially more 
potent on the 32T59K mutant. BuIA[P6O] was 1360-fold, BuIA[P6-fluoro] was 165-
fold, BuIA[P6O(3)] was 132-fold more potent, on 32T59K nAChR than wild type 
32 nAChRs (Fig. 1.5 and Table 1.3).  
Previous findings suggested that  2Thr59 was a determinant of the -conotoxin 
BuIA ability to kinetically discriminate between 2 and 4 containing nAChRs (23).  In 
light of the increased potency of BuIA[Pro6] analogs for 32T59K, we examined the 
effects of Thr and Lys on the off-rates of BuIA Pro6 analogs. α-Conotoxins BuIA[P6O] 
and BuIA[P6-fluoro]. Each had rapid reversibility for  nAChRs.  In contrast these 
analogs each had slower reversibility for the  nAChRs. In addition when 2Thr59 is 
changed to Lys, block by each of the peptides is slowly reversible. Conversely when 
4Lys59 is changed to Thr, block by each of the peptides is rapidly reversed. Thus, 







The acetylcholine binding site is located at the interface of two nAChR subunits.   
The nAChR  subunit sometimes referred to as the “principal” or (+) binding subunit.  A 
binding pocket is created by  subunit residues that form loops known as A, B, and C.  
The  or “complementary” subunit contributes residues to loops known as D, E and F.  
Despite the names, it has become increasingly clear that the  subunit can have 
significant and even dominant effects on agonist and antagonist pharmacology.  Some -
conotoxins show over four orders of magnitude of discrimination between nAChR 
subtypes that contain the same  but different  subunits (11,43,44). -Conotoxin BuIA 
is unusual among the-conotoxins in that it interacts with multiple nAChR subtypes but 
the kinetics of binding are determined by the  subunit.  For a nAChR with a given  
subunit, BuIA is most potent on 2-containing receptors.  Surprisingly, however, the off-
rate kinetics are much slower on 4-containing receptors.   
 In the present study, we synthesized mutants of BuIA to scan for residues that 
might account for the -subunit specific interactions.  Among the mutant peptides, the 
analog in which 4-hydroxyproline was substituted for Pro6 had a three order of 
magnitude reduction in activity at the  nAChR.  In contrast, there was only a three-
fold change in IC50 at the  nAChR.   
Testing of the mutant peptides against mutant receptors revealed interaction of 
Pro6 and residue 59 of the  subunit.  The Pro residues in conotoxin ImI and -




(+) face of the 7 subunit (45,46).  To our knowledge, this is the first demonstration of 
interaction of the conserved Pro with residues of the (-) face of the  subunit. 
nAChR subunits are expressed throughout the nervous system with distinct, but 
overlapping anatomical distribution. This presents a challenge for selectively targeting a 
subpopulation of receptors in a given neuronal tissue.  The present results indicate that 
the Thr59 to Lys difference between 2 and 4 subunits may be used to advantage in 
designing selective conotoxin ligands. Consistent with this, an analog of BuIA, 
BuIA[T5A;P6O] was recently shown to block nicotine-stimulated norepinephrine release 
in hippocampus.  The same analog fails to block nicotine-stimulated dopamine release 
from caudate-putamen (47).  The current study provides mechanistic insight into how the 
analog may achieve this selectivity.  The substitution of hydroxyproline may prevent 
binding at an  interface that mediates dopamine release, while sparing interaction at 












 BuIA analogs 
 












The sequences of all toxin analogs used in the study are shown. 
The mutated residues are bold and underlined. 
¹-Proline – 4(R)-hydroxyproline mutation;  
²- Proline – 3(R)-hydroxyproline mutation,  
³- Proline – 4(R)-fluoroproline mutation,  











Selected α-conotoxin sequences demonstrate a highly conserved proline residue in the first 
intercysteine loop. 
Peptide Sequence Species Reference 
4/7 family of α-
conotoxins 
   
AnIA CCSHPACAANNQDYC* C. anemone  (25) 
AnIB GGCCSHPACAANNQDYC* C. anemone  (25) 
AnIC GGCCSHPACFASNPDYC* C. anemone  (25) 
AuIA GCCSYPPCFATNSDYC* C. aulicus  (26) 
AuIC GCCSYPPCFATNSGYC* C. aulicus  (31) 
EI RDOCCYHPTCNMSNPQIC* C. ermineus  (27) 
EpI GCCSDPRCNMNNPDYC* C. episcopatus  (28) 
GIC GCCSHPACAGNNQHIC* C. geographus  (29) 
GID IRDγCCSNPACRVNNOHVC C. geographus  (30) 
MII GCCSNPVCHLEHSNLC* C. magus  (15) 
OmIA GCCSHPACNVNNPHICG* C. omaria  (31) 
PeIA GCCSHPACSVNHPELC* C. pergrandis  (32) 
PIA RDPCCSNPVCTVHNPQIC* C. purpurascens  (33) 
PnIA GCCSLPPCAANNPDYC* C. pennaceus  (34) 
PnIB GCCSLPPCALSNPDYC* C. pennaceus  (34) 
SrIA RTCCSROTCRMγYPγLCG* C. spurius  (35) 
SrIB RTCCSROTCRMEYPγLCG* C. spurius  (35) 
Vc1.1 GCCSDORCNYDHPγIC* C. victoriae  (36) 
Lp1.1 GCCARAACAGIHQELC* C. leopardus  (37) 
4/6 family of α-
conotoxins 
   
AuIB GCCSYPPCFATNPDC* C. aulicus  (26) 
4/5 family of α-
conotoxins 
   
Ca1.1 QNCCSIPSCWEKYKCS C. caracteristicus  (38) 
4/4 family of α-
conotoxins 
   
BuIA GCCSTPPCAVLYC* C. bullatus  (18) 
PIB ZSOGCCWNPACVKNRC* C. purpurascens  (39) 
4/3 family of α-
conotoxins 
   
ImI GCCSDPRCAWRC* C. imperialis  (13) 
ImII ACCSDRRCRWRC C. imperialis  (40) 










Table 1.2 continued 
 
Peptide Sequence Species Reference 
3/5 family of α-
conotoxins 
   
CnIA GRCCHPACGKYYSC* C. consors  (41) 
GI ECCNPACGRHYSC* C. geographus  (42) 
GIA ECCNPACGRHYSCGK* C. geographus  (42) 
GII ECCNPACGKHFSC* C. geographus  (42) 
MI GRCCHPACGKNYSC* C. magus  (14) 
Conserved cysteine residues are highlighted in bold-face. Conserved proline is highlighted 
in red and shaded. For post-translational modifications: γ, γ-carboxyglutamate; Z, 























IC50s and calculated coupling energies. 








WT(32) BuIA¹ 5.7 nM 4.6-7.2 nM   
WT(32) BuIA 
[P6O] 





130 nM 81-210 nM   
WT(32) BuIA 
[P6O(3)] 
5.4 M 3.0-10 M   
WT(32) BuIA 
[P7O] 
81 nM 70-94 nM   
32T59K BuIA¹ 0.24 nM 0.19-0.32 nM   
32T59K BuIA 
[P6O] 
11 nM 7.0-17 nM 60 2.4 
32T59K BuIA 
[P6-fluoro] 
0.79 nM 0.58-1.1nM 7.0 1.1 
32T59K BuIA 
[P6O(3)] 
41 nM 28-59 nM 5.5 1.0 
32T59K BuIA 
[P7O] 
1.2 nM 0.9-1.6 nM 2.8 0.61 
32V111I BuIA¹ 9.0 nM 7.6-11 nM   
32V111I BuIA 
[P6O] 
20 M 15-26 M 1.2 0.12 
32V111I BuIA 
[P6-fluoro] 
2.6 M 2.5-2.7 M 12 1.5 
32V111I BuIA 
[P6O(3)] 
10 M 7.9-13 M 1.2 0.11 
32V111I BuIA 
[P7O] 
970 nM 540-1700 nM 7.6 1.2 
32F119Q BuIA¹ 0.74 nM 0.59-0.91 nM   
32F119Q BuIA 
[P6O] 
530 nM 400-700 nM 3.8 0.77 
32F119Q BuIA 
[P6-fluoro] 
36 nM 30-43 nM 2.1 0.44 
32F119Q BuIA 
[P6O(3)] 
1.0 M 0.83-1.2 M 1.4 0.21 
32F119Q BuIA 
[P7O] 
20 nM 16-24 nM 1.9 0.37 




Table 1.3 continued 
 














81 nM 60-110 nM   
WT(34) BuIA 
[P6O(3)] 
510 nM 400-640 nM   
WT(34) BuIA 
[P7O] 
11 nM 9.6-13 nM   
34K59T BuIA 34 nM 29-38 nM   
34K59T BuIA 
[P6O] 
6.6 M 4.2-9.0 M 58 2.4 
34K59T BuIA 
[P6-fluoro] 
410 nM 340-490 nM 4.2 0.84 
34K59T BuIA 
[P6O(3)] 
5.9 M 4.8-7.4 M 9.7 1.3 
34K59T BuIA 
[P7O] 
135 nM 88-210 nM 10 1.3 
Coupling energies were calculated using Eq.2 (see Materials and methods).  
















               
 
Figure 1.1 Mutations in α-conotoxin BuIA differentially affect α3β2 vs. α3β4 
nAChRs. The noncysteine residues of α-conotoxin BuIA were mutated to alanine (A) or 
hydroxyproline (O) and tested on rat α3β2 and α3β4 nicotinic receptors heterologously 
expressed in Xenopus oocytes as described in Materials and methods. Error bars are 






















rat 4         ANAEEKLMDDLLNKTRYNNLIRPATSSSQLISIRLELSLSQLISVNEREQIMTTSIWLKQ 60 
human 4       ANAEEKLMDDLLNKTRYNNLIRPATSSSQLISIKLQLSLAQLISVNEREQIMTTNVWLKQ 60 
rat 2         TDTEERLVEHLLDPSRYNKLIRPATNGSELVTVQLMVSLAQLISVHEREQIMTTNVWLTQ 60 
human 2       TDTEERLVEHLLDPSRYNKLIRPATNGSELVTVQLMVSLAQLISVHEREQIMTTNVWLTQ 60 
        
                                                                     *       *       
rat 4         EWTDYRLAWNSSCYEGVNILRIPAKRVWLPDIVLYNNADGTYEVSVYTNVIVRSNGSIQW 120 
human 4       EWTDYRLTWNSSRYEGVNILRIPAKRIWLPDIVLYNNADGTYEVSVYTNLIVRSNGSVLW 120 
rat 2         EWEDYRLTWKPEDFDNMKKVRLPSKHIWLPDVVLYNNADGMYEVSFYSNAVVSYDGSIFW 120 
human 2       EWEDYRLTWKPEEFDNMKKVRLPSKHIWLPDVVLYNNADGMYEVSFYSNAVVSYDGSIFW 120 
                   
rat 4         LPPAIYKSACKIEVKHFPFDQQNCTLKFRSWTYDHTEIDMVLKSPTAIMDDFTPSGEWDI 180 
human 4       LPPAIYKSACKIEVKYFPFDQQNCTLKFRSWTYDHTEIDMVLMTPTASMDDFTPSGEWDI 180 
rat 2         LPPAIYKSACKIEVKHFPFDQQNCTMKFRSWTYDRTEIDLVLKSDVASLDDFTPSGEWDI 180 
human 2       LPPAIYKSACKIEVKHFPFDQQNCTMKFRSWTYDRTEIDLVLKSEVASLDDFTPSGEWDI 180 
 
 
Figure 1.2 Sequence alignment of rat and human β2 and β4 nAChR subunits. The 
nonconserved residues of the complementary binding site, important for α-conotoxin 
binding, are indicated.  
                             
 
Figure 1.3 Coupling coefficient values for toxin-receptor mutant pairs. Wild type 
and mutant peptides were tested on wild type and mutant receptors heterologously 
expressed in Xenopus oocytes.  The coupling coefficient, Ω, for the magnitude of 
interaction was calculated as described in Materials and methods. Absolute values were 

























                                  
 
Figure 1.4 Concentration-response curves for BuIA[P6O] on rα3β2 and rα3β4 
nAChRs. Substitution 4-trans-hydroxyproline for Pro6 enables the peptide to selectively 
block α3β4 vs. α3β2 nAChRs. 
 












      
     
Figure 1.5 Concentration-response of toxin analogs tested on receptor mutants. 
Concentration-response analysis indicates that Lys59 of the β4 subunit favors toxin 
binding. A, BuIA[P6O], B, BuIA[P6O(3)], C, BuIA[P6-fluoro], and D, BuIA[P7O] show 
higher affinity for the rα3β2T59K receptor variant compared to wild type rα3β2 nAChR.  
BuIA[P6O] is 1360-fold, BuIA[P6-fluoro] is 165-fold,  BuIA[P6O(3)] is 132-fold and 
BuIA[P7O] is 67-fold more potent on rα3β2T59K compared to rα3β2. Error bars are  






      
 










Figure 1.6 Position 59 of the  subunit alters kinetics of toxin unblock. Rat nAChRs 
were expressed in Xenopus oocytes as described in Experimental Procedures. A control 
response (C) to ACh was measured.  Following a 5-minute toxin application, ACh was 
again applied followed by toxin wash-out.  Recovery from toxin block was measured at 1- 
minute intervals.  BuIA[P6O] was applied as indicated to (A) w.t. rat  nAChRs; (B) 
w.t.  nAChRs;  (C) a point mutant of  where Lys59 found in the w.t.   subunit 
was substituted for Thr59 found in the w.t.  subunit; and (D),  a point mutant of  
where Thr59 found in the w.t.   subunit was substituted for Lys59 found in the w.t.  
subunit.  Note in each instance that recovery from toxin block is slower when position 59 
of the  subunit is Lys.    Likewise, BuIA[P6-fluoro] was applied as indicated to (E) w.t. rat 
 nAChRs; (F) w.t.  nAChRs;  (G) a point mutant of  where Lys59 found in 
the w.t.   subunit is substituted for Thr59 found in the w.t.  subunit; and (H),  a point 
mutant of  where Thr59 found in the w.t.   subunit is substituted for Lys59 found in 
the w.t.  subunit.   Note again that recovery from toxin block is slower when position 59 










5’ UNTRANSLATED REGION OF HUMAN α9 SUBUNIT IS CRITICAL TO 









Nicotinic acetylcholine receptors (nAChRs) are ACh-gated ion channels 
implicated in many physiological as well as pathophysiological processes. The role of 
nAChRs in mediating EPSPs at synapses in autonomic ganglia (48,49) and at the skeletal 
neuromuscular junction is well established (50,51). In the CNS, nAChRs are involved in 
modulation of neurotransmitter release (52) and in attention and memory (53,54). The 
pathological conditions where involvement of nAChRs have been implicated include 
Alzheimer's and Parkinson's diseases (55,56), nicotine addiction (57,58) and 
schizophrenia (59,60). Seventeen vertebrate nAChR subunits have been cloned to date 
(α1 through α10, β1 through β4, γ, δ, and ε) (61). The nAChR is formed from five 
subunits, either homomeric receptors (α7, α9) containing five identical subunits or 
heteromeric receptors (for example, α4β2, α3α5β4, α6α4β2β3, or α9α10). 
 α9-containing nAChRs are unique among neuronal nAChRs in that they are found 
mainly outside of the CNS (62-66). Also, unlike other nAChRs, they are inhibited by 
nicotine (62,67,68). α9-containing nAChRs play roles in pain (69-74), inflammation, 
keratinocyte adhesion (75), and in mediating synaptic transmission between the efferent 
olivocochlear fibers and cochlear hair cells (76,77). 
 With advances in molecular biology, it became possible to isolate and sequence 
the genes encoding nAChRs. α9 and α10 subunits were among the last nicotinic receptor 
subunits to be isolated and characterized. The clone encoding the α9 subunit was 
originally obtained from a rat olfactory epithelium cDNA library (62). X. laevis oocytes 
injected solely with rat α9 cRNA yielded homomeric receptors that responded to 100 μM 




subunit was isolated from an adult rat cochlea cDNA library (78). The coinjection of rat 
α9 and rat α10 cRNAs into oocytes resulted in oocytes with ~ 100-fold larger ACh-gated 
currents (IACh) than oocytes injected solely with α9 cRNA. Subsequently, the sequences 
of human α9 and α10 subunits were determined from keratinocytes (75) and inner-ear 
neuroepithelium (79), respectively. 
To study the pharmacological properties of nAChRs, heterologous expression 
systems are often used. Mammalian cell lines such as HEK293 and SH-EP1 cells are 
frequently used to characterize nAChRs (80,81). Besides mammalian cells, oocytes of 
Xenopus laevis, the African clawed frog, have been frequently used for heterologous 
expression. These oocytes provide several advantages for the study of receptors. They are 
large and thus easy to handle and to inject with RNA, have long life-times (several days) 
and can be maintained under relatively simple culture conditions. Oocytes are largely free 
of endogenous receptors that could interfere with the signals of exogenously expressed 
channels/receptors. Thus, oocytes have been extensively used to characterize the 
biophysical and pharmacological properties of nAChRs. They have also been used to 
study the stoichiometry of receptor subunits, the contribution of different subunits to the 
properties of receptors, and the structure-function relationships with various ligands. For 
most nAChRs, oocytes have worked extremely well as an expression host (82-84). 
However, in some instances cRNA-injected oocytes have failed to yield readily 
detectable IACh. For instance, human α9 cRNA-injected oocytes have only small IACh 
compared to oocytes injected with its rat counterpart (85,86). There is no report to date of 
successful functional expression of human α9-containing receptors in mammalian cell 




 The translational efficiency of nAChRs in oocytes is influenced by the structure 
of the injected cRNA (89,90) including the Kozak sequence (91), the secondary structure 
(92,93) and composition of untranslated regions (94,95). The 5' leader sequence 
preceding the coding region plays an important role in the binding of cap-binding 
proteins and in facilitation of translation initiation (96). One approach to improve the 
translation in oocytes is to flank the gene-encoding sequence with the untranslated 
regions of highly translatable proteins of X. laevis, such as β-globin (97,98). When 5’ and 
3’untranslated regions (UTRs) of human interferon- mRNA are replaced by those of X. 
laevis β-globin mRNA, the translation is increased as much as 20- and 300- fold in 
reticulocyte lysates and in X. laevis oocytes, respectively (99). The X. laevis β-globin 
leader sequence exerts its facilitatory effect presumably by increasing translation 
initiation, and not by increasing the binding of limiting factors (97). However, for human 
α9, the addition of the X. laevis β-globin sequence to the 5’ and 3’ UTRs is not sufficient 
to produce high expression levels.  
In this report, we show that the human 9 subunit is the limiting factor in the 
expression of human α9α10 nAChRs in X. laevis oocytes. Furthermore, we found that 
this expression can be substantially improved by the insertion of the 5’ leader sequence of 
alfalfa mosaic virus RNA4 (AMV) to the human α9 5’ UTR.  




 cDNAs encoding α9 and  α10 nAChR subunits from rat were provided by A. B. 
Elgoyhen (University of Buenos Aires, Argentina). The rat α9 cDNA was in a pGEMHE 




pSGEM vector (a modified pGEMHE vector) between EcoRI and XhoI restriction sites. 
cDNAs encoding human α9 and human α10 subunits, in the pGEM-11Zf(+) vector, were 
generously provided by L. Lustig (University of California San Francisco, San Francisco, 
CA). The cDNAs encoding human subunits were subsequently inserted into the pSGEM 
vector between EcoRI and XhoI restriction sites. The oligonucleotides encoding the 
5’leader sequence of alfalfa mosaic virus RNA4 (AMV) were synthesized at the 
University of Utah core facility. The sequence of the synthesized oligonucleotides was as 
follows: sense- 5' GGGTTTTTATTTTTAATTTTCTTTCAAATACTTCCACCG 3'; 
antisense- 
5' AATTCGGTGGAAGTATTTGAAAGAAAATTAAAAATAAAAACCCGC 3'. The 
oligonucleotides were diluted in 10 mM Tris-Cl, pH 8.5 to a final concentration of 107 
μM for sense oligonucleotide and 80 μM for antisense oligonucleotide. 20 μL of each 
oligonucleotide was mixed in an annealing reaction tube. The annealing reaction was as 
follows: exposure to 95 °C for 10 minutes followed by cooling to 25 °C over a period of 
45 minutes. The annealed oligonucleotide was ligated into MCS of pSGEM vector 
between the SacII and EcoRI restriction sites. 
cRNA synthesis 
 
 The NheI enzyme was used to linearize the vector encoding human α9 and human 
α10 subunits. In vitro transcription was performed using the mMessage mMachine T7 kit 
(Ambion, Austin, TX). The reaction was followed by DNase treatment. The cRNA was 
purified with a Qiagen RNeasy kit (Qiagen, Valencia, CA, USA). The cRNA 





Oocyte isolation and injection 
 
 The isolation of the oocytes was performed as previously described (15). Briefly, 
stage IV-V oocytes were isolated from anesthetized adult frog. The oocytes were kept at 
17° C in ND96 (96 mM NaCl, 1.8 mM CaCl2, 2.0 mM KCl, 1.0 mM MgCl2, 5mM 
HEPES, pH 7.1-7.5) supplemented with antibiotics (50 U/mL penicillin, 50 μg/mL 
streptomycin, 50 μg/mL gentamicin). The oocytes were injected with 50.6 nL of cRNA 
and incubated for 1-3 days before recording. The amount of cRNA injected into each 
oocyte varied in different experiments: to compare level of expression of human and rat 
α9α10 receptors, 3.3 ng/oocyte of each subunit cRNA was injected. To compare the level 
of expression of human receptors formed from subunits injected at different ratios, 4.4 ng 
cRNA of each nAChR subunit was injected into individual oocytes when a ratio of (1) is 
indicated and 22 ng cRNA was injected when a ratio of (5) is indicated. For all other 
experiments, 14.4 - 32 ng/oocyte of cRNA was injected. 
Two-electrode voltage clamp recording 
 
 ACh-gated currents were recorded from oocytes as previously described (15). 
Briefly, an oocyte was placed in ~30 μL chamber (4mm diameter X 2mm deep) 
fabricated from Sylgard and gravity-perfused with ND96 at a constant flow rate (~2 
mL/min). The oocyte's membrane potential was held at -70 mV using an OC-725B two-
electrode voltage clamp amplifier (Warner Instrument Corp., Hamden, CT). To evoke 
IACh, the perfusion of ND96 was replaced for 1 second with ND96 containing100 μM 
ACh; such a pulse of ACh was applied once per minute. The peak of the ACh-gated 
current (IACh) was measured and the average of six consecutive IACh responses served as 




 To minimize potential batch-to-batch variability, oocytes from the same isolation 
were used to compare the expression of receptors formed from unmodified and modified 
nAChR subunits. Furthermore, all recordings for a given comparison were performed on 
the same day. 
Data analysis 
 
 Data are expressed as mean ± SEM. Statistical comparisons between two groups 
were done using Student's t-tests, and those between multiple groups were done using 
ANOVA test with Tukey’s post-hoc comparison. 
Results 
 
Human α9α10 nAChRs express poorly in X. laevis oocytes 
 Previous investigations of human and rat α9-containing receptors reported 
difficulties in the expression of human α9-containing receptors (85,86). Consistent with 
these reports, when cRNAs encoding human α9 and human α10 subunits of nAChRs 
were co-injected into oocytes at a 1:1 molar ratio, 100 μM ACh produced small currents 
(Fig. 2.1A top), which on average were 30 ± 3 nA (Fig. 2.1B). Currents of this low 
magnitude are difficult to utilize for medium throughput pharmacological testing. In 
contrast, co-injection of rat α9 and rat α10 subunits yielded large currents (Fig. 2.1A 
bottom) with an average amplitude of 8067 ± 1638 nA (Fig. 2.1B). The difference in 
functional expression between rat α9α10 and human α9α10 nAChRs might be due to the 
inefficient translation of the human α9 or human α10 subunit or both, and this was 






Functional expression of α9 versus α10 subunits 
 In order to assess the influence of α9 vs. α10 subunits on the functional expression 
of α9α10 nAChRs, we injected cRNA encoding subunits from different species (i.e., rat 
versus human) at a 1:1 ratio. When human α9 was co-expressed with rat α10, the current 
amplitude was invariably low in all three batches of oocytes tested, averaging from 5 ± 1 
nA to 50 ± 15 nA (Fig. 2.2 and Table 2.1). When rat α9 was co-expressed with human 
α10, the current was readily detectable (Fig. 2.2 and Table 2.1) and at a level similar to 
that seen after co-injection of rat α9 with rat α10 subunits (Fig. 2.1A bottom and Fig. 
2.1B); the average current amplitude ranged between 732 ± 155 nA and 9755 ± 596 nA, 
depending on which of three batches of oocytes was used. There are at least two possible 
reasons for the low functional expression:  A) rat α10 co-expressed with human α9 
produced functionally impaired receptors or B) human α9 subunits are not translated 
efficiently in oocytes. 
Inefficient translation of the human α9 subunit 
appears to limit assembly of functiona 
l human 9/human 10 receptors 
 When cRNAs encoding human α9 and human α10 subunits were co-injected at a 
1:1 ratio, the IACh rarely reached 1 μA with the average response equal to 142 ± 23 nA. 
Oocytes injected with a 5:1 ratio had currents averaging 5171 ± 748 nA. Injections at a 
1:5 ratio produced oocytes with low average IACh amplitude equal to 6.5 ± 3.9 nA (Fig. 
2.3 and Table 2.2). Thus, more abundant cRNA for the α9 subunit leads to substantially 




suggests that translation of the human α9 subunit is likely a limiting factor in the 
assembly of α9α10 receptors. 
AMV insertion and expression of human α9-containing nAChRs 
Previous investigators have shown that incorporation of 5’UTR of the Xenopus 
laevis β-globin gene facilitates the in vitro translation of different proteins in oocytes and 
other expression systems (97,98,100). In pGEMHE and pSGEM vectors the 5’ leader 
sequence of the receptor subunit includes the 5’UTR of X. laevis β-globin, restriction 
sites of the vector’s multiple cloning site, and the native 5’UTR of the subunit.   
Plant viruses use host translational machinery for replication. RNAs of many 
plant viruses possess efficient translation enhancers (101) that can be used in order to 
improve the translation of recombinant proteins or expression of receptors in 
heterologous systems. Among such enhancers are untranslated regions from different 
viral RNAs. The 5’UTR from alfalfa mosaic virus RNA4, the 3’UTR of brome mosaic 
virus and the 5’leader of tobacco mosaic virus were shown to be able to enhance the 
mRNA translation of foreign proteins (102-106).  
In an attempt to improve the translation of human α9/α10 we modified the 
5’leader sequence of human α9 and human α10 subunits by introducing the 5’UTR of 
RNA4 of alfalfa mosaic virus (AMV) into the multiple cloning site of the pSGEM vector 
(Fig. 2.4B) between SacII and EcoRI sites, after the 5’UTR of β-globin and in front of the 
nAChR subunit. 
 The AMV incorporation improved the functional expression of human α9 
homomeric receptors by 37- to 101-fold, and the human α9α10 heteromeric receptors by 




Despite the variability in the expression levels of human α9 and α9α10 receptors, which 
is also commonly observed for other nAChRs, the large improvement in expression was 
highly reproducible.  
Discussion 
In this study, we determined that the functional expression of human α9 subunits 
of nAChRs in X. laevis oocytes depended on the composition of its 5’untranslated region. 
By introducing the 5’ leader sequence of alfalfa mosaic virus RNA4 into the multiple 
cloning site of the pSGEM vector just preceding the coding region of human α9 or α10 
subunits, we created a vector that gave ~ 70-fold higher expression levels of α9 
homomeric receptors and ~ 80-fold higher expression levels of α9α10 heteromeric 
receptors compared to those achieved with unmodified vectors. 
Since the early demonstration that mRNA encoding nicotinic receptors from 
Torpedo californicus electric organ could produce functional receptors when it is injected 
into oocytes of X. laevis (107,108), oocytes have frequently been used as an exogenous 
expression system to study the pharmacology of nAChRs. In most cases, the receptor 
subunits assemble into functional receptors (83,109,110). However, sometimes the cRNA 
injected into oocytes fails to yield functional receptors. For example, when cRNA 
encoding the α6 subunit is co-injected with cRNA encoding the β2 or β4 subunit, there is 
little or no detectable ACh-gated current (111). In our laboratory, the unmodified cRNA 
of human α9 nAChRs failed to produce functional receptors. Other authors also reported 
difficulties in expressing human α9-containing nAChRs (85,86). The ability of cRNAs of 




with high levels of functional expression suggests that human α9 is a limiting factor in 
the assembly of functional receptors. 
 There are several possible factors that can influence the level of functional 
expression of nAChRs in the X. laevis oocyte system. First, the cRNA composition might 
prevent or interfere with efficient translation. For example, formation of secondary 
structures may take place that prevent efficient binding of cap-binding proteins and 
initiation of translation (91). The nucleotide sequence just preceding the start codon is 
important for translation initiation. In eukaryotes, the optimal sequence surrounding the 
start codon is GCCA/GCCaugG (112). If the purine at the -3 position is changed to a 
pyrimidine, the efficiency of translation initiation might be reduced. Second, a high G+C 
content of mRNA can halt efficient transcription and translation by formation of 
secondary structures. For example, the gene encoding human acetylcholinesterase 
(AChE) is highly G+C rich (65%) which results in the formation of a secondary structure 
in the 5’region (113) that serves as an attenuator of transcription. In addition, two highly 
homologous and highly G+C-rich genes encoding Bungarus and rat acetylcholinesterases 
have strikingly different rates of transcription with approximately equal translation in 
oocyte functional tests (114). The difference in the transcription rate is believed to be 
determined by the differences in the coding sequences.  
The G+C content of human α9 mRNA is 49 % for the gene-coding sequence 
compared to 51% for rat mRNA.   α10 subunits are richer in G+C content   with a 65% in 
the human and 59% in the rat subunit. Thus the G+C content of human α9 is only slightly 
lower than its rat counterpart. Based on the relatively equal G+C composition of human 




it is unlikely that G+C content contributes to the low level of functional expression 
observed from unmodified human α9 subunit in our study.  
The UTR is another factor influencing translational efficiency. It was shown to be 
important for the translation of different proteins in different expression systems. 
Mutations in the UTR affect the translation of aspartyl protease BACE1 protein and 
HT3A receptor (115-117). When the 5’UTR of BACE1 is present, the protein, but not 
mRNA, level in transfected HEK293, COS7 and H4 cells is reduced as much as 90%. 
The inhibitory effect of the 5’UTR is due to the upstream open reading frame (uORF) 
(115,117). Due to their importance, the UTR regions are frequently modified to improve 
translation. For example, it became a common practice to include 5'- and 3'- UTRs of 
Xenopus β-globin into expression vectors to flank the gene-coding region (98). UTRs of 
viruses have also been used to replace native UTRs, which results in improved yields of 
translated proteins or improved functional expression of receptors. For example, the 
5’UTR of tobacco mosaic virus enhances the translation of chloramphenicol 
acetyltransferase and β-glucuronidase in tobacco mesophyll protoplasts, E. coli, and 
Xenopus oocytes (102,104,105,118). The facilitatory effect of the 5’leader is due to 
recruitment of eukaryotic initiation factor 4G  indirectly via heat shock protein 101 (119). 
 The alfalfa mosaic virus is an RNA virus consisting of three genomic RNAs and 
one subgenomic RNA (RNA4). RNA1 and RNA2 encode the replicase proteins P1 and 
P2, whereas RNA3 encodes viral movement protein (MP). RNA4 is 881-nucleotides 
long, with a 661-nucleotide long coding sequence that encodes a coat protein required for 
infectivity and replication of the virus (120). The 5’UTR of RNA4 is 39-nucleotides long, 




Computer-based structure prediction as well as nuclease-sensitivity analysis indicate the 
unstructured character of the 5’leader sequence, which can facilitate cap-independent 
translation initiation (121). This fact might be relevant if cap-dependent translation 
initiation of unmodified human α9 subunit is disrupted. The substitution of the native 
5'UTR with a 37-base-pair AMV RNA4 leader was shown to improve the translation of 
several proteins (104,118). For example, in vitro translation of human interleukin 1β and 
barley α-amylase improved as much as 35-fold (105). Also, the introduction of AMV into 
the 5’leader of GABAA receptors improved the expression of those receptors in X. laevis 
oocytes (118). 
The 5’UTRs of human nicotinic receptors may be an important factor for receptor 
function, considering evidence from other systems suggesting that this region could have 
the regulatory elements important for translation initiation (115,122,123). Many human 
nAChR subunits have upstream uATG repeats (uATGs) and upstream open reading 
frames (uORFs). For example, human α9 has an uORF with a length of 36 codons. 
uORFs are involved in translational regulation of oncogenes by suppressing the level of 
translation (124,125). It is believed that the uORF causes the small ribosomal subunit to 
stall and therefore halt translation initiation (126). How the uORF affects the translation 
of the α9 subunit is an open question. When cRNAs encoding nicotinic receptor subunits 
are injected into oocytes at a 1:1 molar ratio, it is assumed that the two subunits will be 
translated with equal efficiencies so the amount of protein of the two subunits will also be 
produced in a 1:1 ratio. However, different receptor subunits might be translated with 




mRNA stability might be a contributing factor to the observed different levels of 
expression between unmodified human α9-containing receptors and rat α9-containing 
receptors. One of the factors that determines the stability of mRNA is located within 3’-
end of mRNA. In particular, the poly(A) tail is required to ensure high functional stability 
of the mRNA as was shown for rabbit globin protein (127,128). The 3’UTR of the human 
α9 subunit had a short (6 nucleotides) native 3’UTR, followed by the 3’ UTR of Xenopus 
β-globin, followed by a poly(A) tail.  In contrast, the modified construct incorporated the 
5’ UTR of the alfalfa mosaic virus RNA4. This addition may slow degradation of the 
mRNA.  
Another factor that may contributes to the fast turnover of mRNA is an AU-rich 
region at 3’-untranslated region. Many RNA-binding proteins such as ELAV-like 
proteins (HuD, Hel-N1, HuC, HuR) bind to AU-rich regions at the 3’-untranslated region 
of RNA and prevent degradation of mRNA (129). Human α9 as well as rat α9 subunit 
3’UTRs have six non-overlapping AUUUA motifs separated by non-AU nucleotides in a 
U-poor region. In addition, they have one AAAAUUUAAAA motif. 
A second possibility for low expression level of receptors in oocytes is the lack of 
postrtranslational modifications in the oocyte expression system. The possible 
posttranslational modifications of nAChRs include proteolytic cleavage, disulfide bond 
formation, glycosylation, palmitoylation, fatty acid acylation, phosphorylation, 
amidation, hydroxyprolination, proline isomerization, etc. (130-133). The lack of 
functional expression of α6-containing receptors is likely due to posttranslational 
mechanisms, insofar as functionality is achieved when the C-terminus of the α6 subunit is 




elements for efficient receptor function are located outside of ligand-binding domain 
(111).  
 A third possibility is the lack of appropriate chaperones in oocytes. There are 
several chaperones described for nicotinic receptors such as BiP, calnexin, Erp57, and 
RIC3 (134,135), which facilitate proper folding and improve functional expression of 
receptors. Nicotine exposure causes an upregulation of nicotinic AChRs in brain as well 
as in vitro, and a possible explanation of this effect is through the chaperoning by 
nicotine (136-138). The RIC-3 is a chaperone that upregulates the expression of α7 
nAChRs in oocytes (139-142). Interestingly, RIC-3 has no effect on the expression of α9 
receptors (87,143). 
 There are few reports of successful expression of α9 receptors in mammalian cells 
(144). GH4C1 cell line derived from pituitary gland was successfully transfected with rat 
910 receptors (88). Here, the average ACh-evoked currents ranged between 16 pA to 
300 pA. Also, an α9/HT3a chimera, where the N-terminus of rat α9 was fused to the C-
terminus of mouse HT3a receptor, produced functional receptors (145). Mouse α9α10 
receptors were successfully transfected into HEK293 cells (144). The problem of the lack 
of expression of human α9 receptor in mammalian cell lines was addressed in several 
reports (87,144-146). It was shown that co-transfection of human α9 and α10 subunit 
with AChR-associated proteins rapsyn and chaperone RIC-3 in CL4 cells increased the 
cytosolic calcium level after application of 100 μACh but no measurements of ionic 
current from α9-containing receptors were reported (146). It is still an open question as to 




translation, improper folding, and lack of chaperoning or posttranslational modifications 
or a combination of these. 
 In our current study, we observed the effect of the 5'UTR of the human α9 subunit 
on the expression of functional receptor. We conclude that the inefficient expression of 
human α9-containing receptors can be improved by modifying 5’UTR of the cRNA 
encoding the subunit. It is possible that the initiation codon of the original unmodified 
subunit is in unfavorable form such that the small ribosomal subunit fails to associate 
with the RNA. By including the 5’UTR of RNA4 of alfalfa mosaic virus, we were able to 
construct an RNA, which when expressed in X. laevis oocytes, can be used to screen new 
ligands which bind to the α9* receptor (* denotes possibility of other subunits). The 
reasons for the poor ability of α9 receptors (both rat and human) to be expressed in the 
mammalian cells still remain to be explored. 
Transcriptional and translational mechanisms are likely involved in regulation of 
human and rat α9 subunit expression in native tissues. In the rat adrenal medulla 
expression levels of α9, α3, and α7 subunits were determined by quantitative PCR (66) 
and the level was lowest for the α9 subunit.  However, the same study showed that 
transcription of α9, but not α3 and α7 subunits, is upregulated in response to stress. 
Regulation of transcription and translation of nAChRs may also be relevant in the context 
of smoking. The concentration of nicotine in active smoker plasma can be 100 nM to 1 
μM. Chronic exposure to nicotine leads to activation and desensitization of nAChR 
subtypes including α4β2 and α7. As a result, the level of expression of α4β2 nAChRs  is 
increased in the brain (147). Smoking is also associated with carcinogenesis, and 




and bladder cancers. α9 receptors mediate cell proliferation of breast cancer cells, and 
increased α9 nAChR subunit mRNA levels were observed in breast tumor tissues (148). 
Moreover, α9-nAChR mRNA expression was higher in advanced-stage tumors. It was 
also shown that nicotine upregulates the mRNA as well as protein level for α9 receptors 
in breast tumor tissue (148). The mechanism by which nicotine treatment leads to this 
upregulation remains elusive. α9 subunit expression seems to be important for cell 
proliferation, and therefore, the mechanisms, whether transcriptional or translational, that 
control subunit expression might open exciting new avenues for control of tumorigenesis.  
Our findings suggest the involvement of 5’-untranslated region in the efficient expression 
of human α9-containing receptors in oocytes. It remains to be investigated whether 


















Comparison of the functional expression of receptors following co-injection of cRNA for 




Receptor Mean current  
amplitude (nA) 
SEM n 
1 hα9rα10 5 1 4 
1 rα9hα10 732 155 5 
2 hα9rα10 21 7 7 
2 rα9hα10 8200 774 6 
3 hα9rα10 50 15 6 
3 rα9hα10 9755 596 6 






Comparison of the functional expression of receptors upon co-injection of different ratios 
of cRNA for specific subunit.ª 
 
Receptor Mean current 
amplitude (nA) 
SEM n 
hα9(1):hα10(1) 142 23 23 
hα9(5):hα10(1) 5171 748 21 
hα9(1):hα10(5) 6.5 3.9 19 










Receptor Mean current 
amplitude (nA) 
SEM n 
1 α9 7 4 3 
1 α9AMV 268 83 5 
2 α9 5 1 5 
2 α9AMV 372 52 6 
3 α9 8 2 5 
3 α9AMV 785 167 10 










Receptor Mean current 
amplitude (nA) 
SEM n 
1 hα9α10 43  6 5 
1 hα9AMVα10AMV 10813 1739 10 
2 hα9α10 60 11 5 
2 hα9AMVα10AMV 6999 1627 5 
3 hα9α10 237 41 8 
3 hα9AMVα10AMV 9763 1379 8 






                               
 
Figure 2.1. Comparison between the levels of exogenous expression of rat and 
human α9-containing nAChRs in X. laevis oocytes.  
ACh-gated currents were measured in voltage-clamped oocytes as described in 
Methods. (A) Representative traces from an oocyte injected with human α9 and human 
α10 cRNA (top) and rat 9 and rat 10 cRNA (bottom). Robust currents were observed 
with rat cRNA, but only small currents were observed with human cRNA. (B) 
Comparison of the averaged current responses evoked by 100 μM ACh applications from 
oocytes expressing human α9α10 and rat α9α10 receptors. The mean current amplitude 
was 30 ± 3 nA (n = 7 oocytes) for human α9α10 and 8067 ± 1638 nA (n = 7) for rat 





                                                
Figure 2.2. Comparison between the level of expression of human 9/rat 10 
(h9r10) and rat 9/human 10 (r9h10) receptors. 
 Receptors assembled from injection of cRNAs encoding subunits from different 
species have different levels of functional expression.  hα9rα10 nAChRs were expressed 
with low efficiency compared to rα9hα10. Results from three batches of oocytes are 
shown. All oocytes of a given batch were injected on the same day and recordings 
performed 2 days later. Values of mean current amplitudes are given in Table 2.1. 












                                                 
Figure 2.3. Comparison of functional receptor expression following injection of 
different ratios of receptor subunit cRNA.  
Differing subunit ratios of cRNA were injected into oocytes and the resulting 
levels of expression of functional receptors were compared. Recordings were performed 
2 days after injection. The data from oocytes of four different batches were combined to 
determine the mean current amplitudes. Values are given in Table 2.2. A one-way 
ANOVA test with Tukey’s post-hoc comparison indicated a significant difference 
between hα9(1):hα10(1) vs. hα9(5):hα10(1), p<0.001, and between hα9(5):hα10(1) vs. 
hα9(1):hα10(5), p<0.001. There was no significant difference between hα9(1):hα10(1) 






Figure 2.4. Comparison of the 5' untranslated regions in human α9, human α10, rat 
α9, and rat α10 subunits. 
(A) Native 5’UTRs of subunits are between the restriction site and the start codon. 
(B) The modifications made to the 5' untranslated region of human α9 and α10 subunits 
are shown. The 5'UTR of RNA4 of the alfalfa mosaic virus coat protein was inserted into 
the multiple cloning site of the pSGEM vector between SacII and EcoRI sites. The 






Figure 2.5. AMV improves the level of functional expression of α9-containing 
nAChRs. 
(A) Representative traces and (B) comparisons of the levels of functional 
expression of homomeric human α9 receptors encoded by cRNA without (A, top) and 
with (A, bottom) AMV. The results are from three different batches of oocytes, each 
isolated from a different frog and recorded on 3
rd
 day after injection, are presented. (C 
and D) Comparison of the level of expression of heteromeric receptors. Recordings were 
conducted on the second day after injection. Values for mean current amplitude are 





INTERACTION BETWEEN NICOTINIC ACETYLCHOLINE 







Neuronal nAChRs are present ubiquitously throughout the CNS. Presynaptically 
located receptors modulate release of neurotransmitters such as glutamate, serotonine and 
dopamine (149-152). Activation of postsynaptically located nAChRs causes 
depolarization, increase in intracellular calcium and activation of intracellular signaling 
mechanisms (3). The organization of the nervous system is so complex that a single nerve 
terminal might harbor different classes of receptors, such as purinergic and nAChRs 
(153). 
Purinergic P2X receptors are ionotropic channels permeable to cations. They have 
trimeric organization with homomeric (P2X1-P2X5, P2X7) or heteromeric (P2X1/2, P2X1/4, 
P2X1/5, P2X2/3, P2X2/6, P2X4/6) structure formed from P2X1- P2X7 subunits (154-156). 
These receptors are expressed throughout body and are involved in pain, inflammation, 
cancer and other pathophysiological processes (157-161). 
nAChRs and purinergic receptors colocalize in several brain regions as well as 
outside of the CNS. For example, nAChRs colocalize with P2X receptors in the guinea 
pig myenteric neurons, in rat and guinea pig sympathetic neurons, and the receptors 
physically interact with each other (162-165). The nicotinic and purinergic receptors 
interact to control the release of glutamate in hippocampus (166).  
In outer hair cells the α9α10 nAChR mediates synaptic transmission between 
efferent olivocochlear neurons and outer hair cells (167). There are several purinergic 
receptors present in outer hair cells along with α9α10 nAChRs. Among them are 
ionotropic P2X1, P2X2, P2X4, and to a lesser degree P2X7, and metabotropic P2Y1, P2Y2, 
and P2Y4 receptors (168). It was shown that ATP- induced Ca
2+




inhibited by acetylcholine, and this effect is sensitive to α-bungarotoxin (169) suggesting 
an interplay between nicotinic and purinergic receptors. One possible pair that could 
interact with each other includes α9α10 nicotinic receptor and P2X4 purinergic receptor. 
Immune cells are another location where nicotinic and purinergic receptors 
colocalize. mRNAs of different nAChRs were detected in immune cells. Transcripts for 
nicotinic α2, α5, α6, α7, α10, and β2 subunits were found by RT-PCR in mononuclear 
leukocytes, bone-marrow derived dendritic cells and macrophages of C57BL/6J mice 
(170). Expression of α9 and α10 subunits was demonstrated in human T- and B-
lymphocytes (171). The activation of the α7 receptor is believed to have anti-
inflammatory effects (172,173). The role of α9α10 nAChRs in immune cells is at the 
beginning of being understood. It was shown in several studies that α9α10 antagonists 
reduce the number of immune cells at the site of injury in an animal model of neuropathic 
pain (70). Also, a recent study showed that onset of experimental autoimmune 
encephalomyelitis is delayed and the severity of the disease is attenuated in α9 knockout 
mice, an observation suggesting involvement of the α9 subunit in proinflammatory 
mechanisms (174). 
Among purinergic P2X receptors, the predominant subtype present in immune 
cells includes P2X7 (175,176). Activation of this receptor leads to increased release of the 
proinflammatory cytokine interleukin-1β (177). The genetic ablation of P2X7 receptors 
results in reduced chronic inflammatory and neuropathic pain (178-180) as well as in 
suppressed development of experimental autoimmune encephalomyelitis (181), but see 
Chen et al. (182). Together with P2X7, P2X4 is also believed to play an important role in 




prostaglandin E2 (PGE2) release via phosphorylation of p38MAPK which leads to 
inflammatory pain initiation (184). The inhibition of the P2X4 receptor has anti-
inflammatory effects. For example, genetic ablation of the P2X4 receptor prevents pain 
hypersensitivity in inflammation (185).  
 We investigated the idea that α9α10 nAChRs interact with P2X4 receptors and/or 
with P2X7 receptors. The interaction was tested by evaluating the character of response 
from coapplication of ACh and ATP when two receptors are coexpressed in oocytes of 
Xenopus laevis. We thought if the receptors interact and one inhibits another then the 
current response from coapplication of both agonists will be a fraction of the predicted 
summation of responses from individual agonists. We also compared the agonist 
sensitivities for both receptors when they were present alone in oocytes or when α9α10 
and P2X4, as well as α9α10 and P2X7 receptors were coexpressed. 
Materials and methods 
cRNA preparation and injection 
cDNA for rat α9 and α10 subunits were provided by A.B.Elgoyhen (Universidad 
de Buenos Aires, Buenos Aires, Argentina), and were in pGEMHE and pSGEM vectors, 
respectively. cDNAs encoding rat P2X4 and P2X7 were provided by Daryl Davies 
(University of Southern California, Los Angeles, CA) in pcDNA3 vector (Invitrogen, 
Carlsbad, CA). cRNAs were in vitro transcribed using T7 mMessage mMachine kit 
(Ambion, Austin, TX) from linearized cDNAs. The concentration of cRNA was 





Two-electrode voltage clamp 
Oocytes of stage IV-V were dissected from African clawed frog following the 
protocol described in details elsewhere (15). Oocytes were injected with 10 – 60 
ng/oocyte of cRNA. The injected oocytes were kept in ND96 solution (96 mM NaCl, 1.8 
mM CaCl2, 2 mM KCl, 1.0 mM MgCl2, 5 mM HEPES, pH 7.1-7.5) supplemented with 
antibiotics (50 U/mL penicillin, 50 μg/mL streptomycin, 50 μg/mL gentamicin). The 
recordings were conducted 1-6 days after injection. 
Two-electrode voltage clamp was done as described in the literature (15) using 
voltage-clamp amplifier (OC-725B, Warner Instrument Corporation, Hamden, CT). The 
membrane potential was kept at -70 mV. The oocytes were placed into ~200 μL bath 
custom made out of pipette tip and perfused with ND96 or barium-substituted ND96 (96 
mM NaCl, 1.8 mM BaCl2, 2 mM KCl, 1.0 mM MgCl2, 5 mM HEPES, pH 7.1-7.5). 
Agonists were bath applied automatically by pump in the volume of 20 μL while the 
solution flow was stopped.  
For concentration-response curve determination, agonists of increasing 
concentrations were delivered manually in a volume of 20 μL while the flow of solution 
was stopped. The agonists concentration-response curves were fit using sigmoidal curve-









Interaction between rat α9α10 and rat P2X4 receptors 
 α9α10 nAChRs co-localize with P2X4 receptors in several places, such as outer 
hair cells and  immune cells. In outer hair cells ACh inhibits ATP-evoked response (169). 
 We tested the hypothesis of interaction between rat α9α10 and purinergic P2X4 
receptors. Acetylcholine activates rat α9α10 receptors with an EC50 value of 13.8 μM 
(78). In our experiments we used 100 μM agonists in order to activate receptors. P2X4 
receptors are activated by ATP with EC50 value equal to 6.9 ± 0.8 μM (186). 100 µM 
ATP was used to activate P2X4 receptors. Agonists were delivered individually in a bolus 
of 20 μL to activate either α9α10 or P2X4 receptors. This was followed by 20 μL 
application of both agonists at 100 μM concentration each. We assumed that if receptors 
function independently, then the resultant current from coapplication of agonists 
(IACh/ATP) would be approximately equal to the sum of currents from each agonist (IACh + 
IATP), the so called predicted current. If one receptor inhibits another, then the actual 
current from coapplication of agonists would be less than the predicted current.  
 When tested under similar conditions, oocytes showed inconsistent results. 
Roughly half of the tested oocytes (n=6) had currents from agonist coapplication less 
than the predicted currents, suggesting inhibition (Fig. 3.1 and Table 3.1). The actual 
current was 76% of predicted current. Another half of oocytes (n=6) showed a purely 
additive character of current, suggesting independent function for receptors (Fig. 3.2 and 
Table 3.2). The actual currents in these oocytes were equal to or even exceeded the 




Due to the inconsistency in the results we undertook an alternative approach. We 
measured agonist sensitivities for both α9α10 and P2X4 receptors under two experimental 
conditions: when receptors were present alone in oocytes and when they were 
coexpressed. We assumed that if receptors were physically coupled to each other, then 
agonist sensitivity of one might be affected by the presence of another receptor even 
when the other receptor is not activated. The results indicated ~1.6-fold rightward shift in 
ATP sensitivity for P2X4 receptors when they were coexpressed with α9α10 receptors 
(Fig. 3.3 and Table 3.3) with EC50 equal to 10 μM for P2X4 receptors alone and 16 μM 
for P2X4 receptors coexpressed with nicotinic receptors (all measurement were conducted 
in regular ND96 solution). The ACh sensitivities measured on rat α9α10 receptors were 
similar when receptors were expressed alone (EC50 = 15 μM) and when they were 
coexpressed (EC50 = 11 μM) (Fig. 3.3 and Table 3.4).  
Oocytes of Xenopus laevis frog are used routinely as a heterologous system to 
study different receptors and channels. The advantage of oocytes is in relative absence of 
endogenous channels that might influence the results of the studies. However, oocytes do 
express endogenous calcium-sensitive chloride-channels (ICl(Ca)) (187-189) that might 
interfere with the recordings from calcium-permeable receptors such as α9α10 and P2X4 
(190). In order to avoid contribution of ICl(Ca) to the results we repeated the above 
experiment in Ba-substituted ND96, where 1.8 mM CaCl2 was replaced by 1.8 mM 
BaCl2. 
 The results were similar to the results in normal ND96 for P2X4 and α9α10 
receptors (Fig 3.3 and Tables 3.3 and 3.4). The EC50 for ATP on P2X4 receptors alone 




observed reduction in ACh sensitivity on α9α10 receptors in the presence of barium, in 
regular ND96 the EC50 was equal to 15 μM compared to 49 μM in Ba-ND96. For α9α10 
receptors coexpressed together with P2X4 receptors, the ACh EC50 increased from 11 μM 
to 55 μM when calcium was substituted with barium (Fig. 3.4 and Table 3.4). EC50s for 
ATP on P2X4 receptors were similar in regular and Ba-ND96 (Fig. 3.3 and Table 3.3).  
Interaction between rat α9α10 and P2X7 receptors 
P2X7 receptors are the predominant purinergic receptor subtype present in 
immune cells, such as lymphocytes, macrophages/monocytes, and mast cells where they 
mediate release of proinflammatory cytokines (155,177,191). Immune cells also express 
subunits for nicotinic acetylcholine receptor (170,192,193). Recent work by Mikulski et 
al. (194) suggested possible interplay between nicotinic and purinergic receptors in rat 
alveolar macrophages. Even though the authors were not able to record ACh-evoked 
current from macrophages, and involvement of metabotropic P2Y receptors was 
suggested, we tested the hypothesis of interaction between α9α10 and P2X7 receptors.  
P2X7 receptors are unique among all other purinergic P2X receptors in their ability 
to change permeability to different ions with prolonged activation time (155). These 
receptors are highly permeable to calcium ions and less sensitive to agonist ATP 
compared to other P2X receptors with EC50 ranging from 2 to 4 mM depending on the 
report (195). In our study we used 1 mM ATP to activate receptors. Due to high calcium 
permeability of both P2X7 and α9α10 receptors and possibility of interference from 
calcium-sensitive chloride channels endogenously expressed by oocytes, we conducted 




The average current amplitude for rat P2X7 receptors when activated by 1 mM 
ATP was relatively low compared to rat α9α10 nAChRs activated by 100 μM ACh in 
barium-containing ND96, which makes comparison between predicted current and actual 
current from coapplication of both agonists difficult. We therefore also used 10 mM 
choline to activate rat α9α10 receptors. Choline is a partial agonist of rat α9α10 receptors, 
with an EC50 equal to 3 μM (78). The results demonstrated lack of interaction between 
two receptors, with current from coapplication of agonists equal to the sum of responses 
from individual agonists (Figure 3.5 and Table 3.5).  
We also measured agonist sensitivities for ACh and ATP on rat α9α10 and P2X7 
receptors under two experimental conditions: when receptors were expressed alone in 
oocytes and when they were coexpressed. The EC50 were similar for both agonists 
independent of whether the receptors were alone or coinjected. The ACh EC50 on rat 
α9α10 alone was equal to 40 μM, n=8, and it was 46 μM, n=7 when receptors were 
coexpressed together with P2X7. The ATP EC50 was 2.2 mM, n=3 for P2X7 alone and 1.6 
mM, n=6 for P2X7 coinjected with rat α9α10 receptor (Figure 3.6 and Tables 3.6 and 3.7). 
Discussion 
 The main conclusion from the study is that we were unable to find conclusive and 
highly reproducible evidence that would demonstrate interaction between rat α9α10 and 
P2X4 receptors or between rat α9α10 and P2X7 receptors. The variability in the results 
with coapplication of agonists in case of α9α10 - P2X4 pair might point to the inability of 
the currently used heterologous expression system to detect interaction in all instances. 
The variation in the results could be explained by the different level of plasma membrane 




then the interaction can be detected only when the level of receptor expression is high 
enough to guarantee juxtaposition of interacting receptors. The dependence of detection 
of cross-inhibition on the channel membrane density was suggested for α3β4 – P2X2 
interaction (163).  
 The slight (1.6-fold) rightward shift in the ATP sensitivity for rat P2X4 receptors 
when they were coexpressed with rat α9α10 receptors compared to when they were alone  
might be within experimental error as far as the ATP EC50 in the literature ranges from 1      
to 10 μM (196-199). However, the persistent character of the shift, observed in regular 
ND96 as well as in barium-substituted ND96 could point to the influence from α9α10 
nAChRs. The changes in agonist sensitivities for both ACh and ATP were observed for 
rat α3β4 and P2X2 receptors expressed heterologously in HEK293 cells (164). These 
changes were explained by ability of one receptor to inhibit another even without being 
activated. 
 Nicotinic acetylcholine and purinergic receptors belong to two distinct classes of 
ligand-activated ion-channels. Despite their structural and pharmacological differences, 
they are involved in similar physiological processes. For example, activation of P2X7 
purinergic receptors in immune cells leads to increase in release of proinflammatory IL-
1β cytokine. Similar to purinergic receptors, α9 subunit might also be involved in 
proinflammatory mechanisms (174). The presence of unrelated receptors in similar 
locations and action of ACh and ATP as cotransmitters raise questions about the 
possibility of functional interaction between receptors. For example, nicotinic and 
purinergic receptors are present on presynaptic membranes of glutamatergic neurons of 




sympathetic neurons, nicotinic and purinergic receptors inhibit each other, as was shown 
for rat and guinea pig neurons (200,201).  
 Nicotinic and purinergic receptors are colocalized and physically interact with 
each other in myenteric neurons. In cultured myenteric neuons as well as in HEK-293 
cells expressing α3β4 and P2X2 receptors coapplication of 3 mM ACh and 1 mM ATP 
evokes current which is a fraction of predicted summary response assuming that receptors 
function independently (162). The mechanism by which two receptors interact is through 
physical interaction where the intracellular loop of the nAChR interacts with the C-
terminus of the purinergic receptor (164). Inhibitory interactions between rat α3β4 and 
P2X2 as well as between α3β4 and P2X4 receptors were also shown in Xenopus laevis 
oocytes (163). Fluorescence resonance energy transfer analysis showed that α4β2 and 
P2X2 receptors are localized within 100 nm from each other (202).   
 The colocalization of receptors belonging to different families, such as purinergic 
and nicotinic acetylcholine is intriguing as far as neurotransmitters activating both 
receptors can be present simultaneously. For example, during inflammation, ATP as well 
as ACh is present at the site of injury. When both agonists are present, they can activate 
highly calcium-permeable receptors (α7 and α9α10 as well as P2X4 and P2X7) leading to 
the amplified increase in calcium influx. The inhibitory interaction between nicotinic and 
purinergic receptors could be a mechanism by which calcium-ion flow and neuronal 



















SEM % of 
predicted 
1 9041 213 3071 114 12179 9517 72 78 
2 16321 580 8408 423 24729 16931 545 68 
3 23811 315 7451 458 31263 25093 512 80 
4 15620 905 9809 409 25429 20752 613 82 
5 12251 212 14173 102 26424 17634 187 67 
6 10270 32 4276 101 14546 12322 231 85 
 
Table 3.2 
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104 7262 9270 
 
267 128 
2 634 23 470 17 1104 2877 100 261 
3 3656 220 2771 103 6427 11468 297 178 
4 225 5 525 31 750 1065 47 142 
5 8828 205 4031 204 12859 13678 212 106 






EC50 values for ATP on rat P2X4 receptors under different experimental conditions. 
Solution Receptor EC50, μM 95% CI, μM Hillslope 95% CI n 
ND96 P2X4 10 6-17 1.5 0.5-2.5 3 
ND96 α9α10 + P2X4 16 12-20 1 0.8-1.4 6 
Ba-ND96 P2X4 9.8 9-10 1.7 1.5-1.8 16 
Ba-ND96 α9α10 + P2X4 16 14-17 1.2 1.1-1.3 14 
 
Table 3.4 
EC50 values for ACh on rat α9α10 receptors under different experimental conditions. 
Solution Receptor EC50, μM 95% CI, μM Hillslope 95% CI n 
ND96 α9α10 15 13-17 1.5 1.2-1.7 3 
ND96 α9α10 + P2X4 11 9-13 1.4 1-1.7 7 
Ba-ND96 α9α10 49 41-59 0.8 0.7-0.9 6 
Ba-ND96 α9α10 + P2X4 55 45-67 0.9 0.7-1 4 
 
Table 3.5 















SEM % of 
predicted 
1 301 6 275 13 576 545 4 95 
2 353 6 307 6 660 622 9 94 







EC50 for ACh on rat α9α10 alone and coinjected with rat P2X7 in Ba-ND96. 
Receptor EC50, μM 95% CI Hillslope 95% CI n 
α9α10 40 38-42 1.1 1.0-1.2 8 
α9α10 + P2X7 46 43-48 1.1 1.0-1.2 7 
 
Table 3.7 
EC50 for ATP on rat P2X7 alone and coinjected with rat α9α10 in Ba-ND96. 
Receptor EC50, mM 95% CI Hillslope 95% CI n 
P2X7 2.2 2.1-2.3 1.4 1.3-1.5 3 
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Figure 3.1 Representative traces (A) and bar graph (B) summarizing the results 
suggesting interaction between rat α9α10 and P2X4 receptors. A) The actual IACh/ATP  
is smaller than the predicted current (IACh + IATP) suggesting inhibition between receptors. 
B) The data are a summary from six oocytes’ individual values which are presented in 
Table 3.1. IACh = 14552 ± 2191 nA; IATP = 7865 ± 1632 nA; IACh/ATP predicted = 22417 ± 
3038 nA ; IACh/ATP actual = 17042 ± 2294 nA. The oocytes were injected with 10 – 60 
ng/oocyte of RNA, and with 1:1 ratio for α9 and α10 subunits. The recordings were 
conducted 1 to 6 days post/injection. The delivery of agonists was according to the 
procedure described in Materials and methods. There is a ns difference between IACh/ATP 
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Figure 3.2 Representative traces (A) and bar graph (B) summarizing the results 
suggesting independent function of rat α9α10 and P2X4 receptors heterologously 
expressed in oocytes of Xenopus laevis frog. A) The actual IACh/ATP  is bigger (130%) 
than the predicted current (IACh + IATP) suggesting no inhibition between receptors. B) 
The data are a summary from six oocytes, individual values for which are presented in 
Table 3.2. IACh = 3958 ± 1341 nA; IATP = 1941 ± 628 nA; IACh/ATP predicted = 5901 ± 
1838 nA ; IACh/ATP actual = 7535 ± 2002 nA. The oocytes were injected with 13 – 53 
ng/oocyte of RNA, and with 1:1 ratio for α9 and α10 subunits. The recordings were 






Figure 3.3 Concentration-response curves for ACh and ATP. EC50s for ACh and ATP 
on rα9α10 and P2X4 were determined under two experimental conditions: when receptors 
were alone and when they were coexpressed. The experiments were conducted in regular 




                              
Figure 3.4 Comparison between ACh EC50 in calcium vs. barium-containing ND96. 
When calcium chloride was substituted with barium chloride the EC50 shifted to the right. 





















                                            
Figure 3.5 Graphical representation of results for rat α9α10 – P2X7 interaction. 
The data are a summary from three oocytes individual values of which are presented in 
Table 3.5. IACh/ = 372 ± 47 nA. IATP = 430 ±139 nA. IACh/ATP predicted = 802 ± 185 nA.  
IACh/ATP actual = 754 ± 172 nA. The oocytes were injected with 20 ng/oocyte of  α9 RNA, 
21 ng/oocyte of α10 RNA, and 41 ng/oocyte of P2X7 RNA.The recordings were 
conducted 2-3 days post/injection. There is nonsignificant difference between IACh/ATP 
predicted and IACh/ATP actual, p>0.05, assessed by t-test. 
 










Figure 3.6 Concentration-response curves for ACh and ATP on rat α9α10 and rat 
P2X7. A) Concentration-response curve for ACh EC50 on rat α9α10 expressed alone in 
oocytes is identical to the curve for ACh EC50 on rat α9α10 coexpressed with rat P2X7 
receptors. The EC50 values are presented in Table 3.6. B) Similar to ACh, ATP activates 
rat P2X7 receptors with similar potency independent whether receptors are alone or 
coexpressed with α9α10 receptors. The values for EC50s and Hillslopes with 95% CI are 
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